In this study, we used two independent cohorts of breast cancer specimens to demonstrate the suitability of an ELISA-like immunoassay, the QDB method, for absolute quantitation of Her2 protein levels to meet the need of daily clinical practice. Here, ERBB2 is linked to breast carcinoma.